Press release
Revolutionary AI Partnership: CallSpot.ai to Showcase Revolutionary Calling Tech at Megamix Business Expo
CallSpot.ai is revolutionizing small business sales by making over 1,000 calls per hour using bots that sound indistinguishable from humans.
The Megamix Expo, scheduled for August 7-8, 2024, at the Ontario Convention Center, will feature a special workshop led by Mike Kraft, the founder of CallSpot.ai. Kraft will focus on AI technologies and strategies that can help small businesses struggling to adapt in a rapidly changing market. This workshop aims to provide valuable insights and practical solutions to leverage AI for business growth and customer engagement.
"CallSpot.ai is capable of making more than 1,000 calls in an hour, elevating small business sales potential to unprecedented heights with bots that sound and speak like real humans," said Mike Kraft, Founder of CallSpot.ai
As pioneers in deploying conversational voice AI for sales and customer service, CallSpot.ai has perfected the blend of cutting-edge technology and the human touch. From educating leads and overcoming objections to booking and transferring calls, this is just one technology that will be covered in the workshop to help small businesses reach new heights.
The Megamix Expo has established itself as a premier networking event for businesses in the Inland Empire. With the addition of CallSpot.ai's workshop, organizers expect to attract a wider range of participants, from small businesses looking to innovate to large corporations interested in the latest AI advancements.
For more information about the Megamix Expo and the AI workshop, visit www.megamixexpo.com. or www.callspot.ai
Media Contact
Company Name: MegaMix Expo
Contact Person: Tony Chi-Su Gutierrez
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=revolutionary-ai-partnership-callspotai-to-showcase-revolutionary-calling-tech-at-megamix-business-expo]
Country: United States
Website: https://www.megamixexpo.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Revolutionary AI Partnership: CallSpot.ai to Showcase Revolutionary Calling Tech at Megamix Business Expo here
News-ID: 3590993 • Views: …
More Releases from ABNewswire
Excessive Daytime Sleepiness Pipeline Insight 2025: Amneal's FDA Approval of Sod …
Excessive Daytime Sleepiness (EDS) is a key symptom of narcolepsy, obstructive sleep apnea, idiopathic hypersomnia, and other neurological disorders. It causes overwhelming fatigue, sudden sleep attacks, and cognitive impairment, significantly affecting daily life and safety. Current treatments, including stimulants, wake-promoting agents, and sodium oxybate, have limitations such as tolerance, side effects, and varying efficacy in some patients.
DelveInsight's "Excessive Daytime Sleepiness - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights a diverse and growing…
Acute Myeloid Leukemia Pipeline Insight 2025: Akeso's FDA ODD for Ligufalimab, 1 …
The acute myeloid leukemia (AML) treatment pipeline is undergoing a profound transformation, with innovative therapies advancing beyond traditional chemotherapy toward precision, immune-based, and regenerative approaches. AML, an aggressive hematologic malignancy, continues to present high relapse rates and poor long-term survival despite decades of therapeutic progress, underscoring the urgent unmet need.
DelveInsight's "Acute Myeloid Leukemia - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a comprehensive analysis of a rapidly expanding portfolio of over 100+…
Dystrophic Epidermolysis Bullosa Pipeline Insight 2025: Krystal Biotech's FDA La …
Dystrophic epidermolysis bullosa is a rare and debilitating genetic skin disorder characterized by extreme skin fragility, painful blistering, chronic wounds, and risk of scarring and squamous cell carcinoma. For decades, treatment options were largely limited to supportive wound care, pain management, and infection control, leaving a massive unmet medical need for disease-modifying therapies.
DelveInsight's "Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights a dynamic and rapidly advancing therapeutic landscape, with…
Why Alta Is The AI Styling App Fashion Lovers Have Been Waiting For
How to use the VOGUE and ELLE acclaimed styling app
NEW YORK, NY - September 16, 2025 - Alta users are obsessed with their look-alike Alta Avatars, made available through AI styling app Alta. With features such as trip planning, closet stats, event styling, shopping recommendations, and daily outfit suggestions, Alta has been described as "the AI-powered closet app...bringing our Cher Horowitz-inspired dreams to life" by leading fashion publications VOGUE [https://www.voguebusiness.com/story/technology/9-fashion-tech-startups-to-watch-according-to-investors]and…
